Delaware | 005-79588 | 62-1715807 | ||
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 8.01 | Other Events. |
On October 13, 2008, GTx, Inc. issued a press release announcing the results of its Phase II cancer cachexia clinical trial, a copy of which is furnished as Exhibit 99.1 to this Current Report. |
ITEM 9.01 | Financial Statements and Exhibits. |
(c) | Exhibits |
Exhibit | ||
Number | Description | |
99.1
|
Press Release issued by GTx, Inc. dated October 13, 2008 |
GTx, Inc. |
||||
Date: October 14, 2008 | By: | /s/ Henry P. Doggrell | ||
Name: | Henry P. Doggrell | |||
Title: | Vice President, General Counsel/Secretary | |||